title: Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome.
abstract: BACKGROUND
  Omega-3 poly-unsaturated fatty acids (ω-3 PUFAs) have demonstrated to be beneficial in the prevention of cardiovascular disease, however, the mechanisms by which they perform their cardiovascular protection have not been clarified. Intriguingly, some of these protective effects have also been linked to HDL. The hypothesis of this study was that ω-3 PUFAs could modify the protein cargo of HDL particle in a triglyceride non-dependent mode. The objective of the study was to compare the proteome of HDL before and after ω-3 PUFAs supplemented diet.
  
  
  METHODS
  A comparative proteomic analysis in 6 smoker subjects HDL before and after a 5 weeks ω-3 PUFAs enriched diet has been performed.
  
  
  RESULTS
  Among the altered proteins, clusterin, paraoxonase, and apoAI were found to increase, while fibronectin, α-1-antitrypsin, complement C1r subcomponent and complement factor H decreased after diet supplementation with ω-3 PUFAs. Immunodetection assays confirmed these results. The up-regulated proteins are related to anti-oxidant, anti-inflammatory and anti-atherosclerotic properties of HDL, while the down-regulated proteins are related to regulation of complement activation and acute phase response.
  
  
  CONCLUSIONS
  Despite the low number of subjects included in the study, our findings demonstrate that ω-3 PUFAs supplementation modifies lipoprotein containing apoAI (LpAI) proteome and suggest that these protein changes improve the functionality of the particle.
authors.affiliation: Laboratorio de Investigación Molecular and Unidad de Lípidos, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria (IIS), Zaragoza, Spain. elena.burillo@fjd.es
authors.forename: Elena
authors.initials: E
authors.lastname: Burillo
authors.forename: Rocío
authors.initials: R
authors.lastname: Mateo-Gallego
authors.forename: Ana
authors.initials: A
authors.lastname: Cenarro
authors.forename: Sarah
authors.initials: S
authors.lastname: Fiddyment
authors.forename: Ana M
authors.initials: AM
authors.lastname: Bea
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Jorge
authors.forename: Jesús
authors.initials: J
authors.lastname: Vázquez
authors.forename: Fernando
authors.initials: F
authors.lastname: Civeira
mesh_terms: D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood / Q000302:isolation & purification; D043303:Aryldialkylphosphatase / Q000097:blood / Q000302:isolation & purification; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D002846:Chromatography, Affinity; D051152:Clusterin / Q000097:blood / Q000302:isolation & purification; D019587:Dietary Supplements; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood* / Q000302:isolation & purification; D008297:Male; D008875:Middle Aged; D020543:Proteome / Q000302:isolation & purification / Q000378:metabolism; D012907:Smoking / Q000009:adverse effects / Q000097:blood
chemical_list: C505693:APOA1 protein, human; D016632:Apolipoprotein A-I; C495242:CLU protein, human; D002316:Cardiotonic Agents; D051152:Clusterin; D015525:Fatty Acids, Omega-3; D008075:Lipoproteins, HDL; D020543:Proteome; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human